Volume 27, Number 11—November 2021
Dispatch
Co-infection with Legionella and SARS-CoV-2, France, March 2020
, and COVID-19 diagnosis HCL consortium1
Table
Patient demographics, underlying conditions, and risk exposures for patients with LD, with and without co-occurring COVID-19, France, 2020*
| Patient no. |
LD-positive, COVID-19–negative |
LD- and COVID-19–positive |
LD- and COVID-19–positive patient details |
||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
|||
| Demographics† | |||||||||
| Sex | M:F ratio 23:18 | M:F ratio 6:1 | M | M | M | F | M | M | M |
| Age, y | Median (range), 67 (36–96) | Median (range), 72 (37–83) | 72 | 71 | 71 | 83 | 73 | 73 | 37 |
| ICU admission |
10/31 (32) |
7/7 (100) |
Y |
Y |
Y |
Y |
Y |
Y |
Y |
| Outcome† | |||||||||
| Recovered | 7/42 (17) | 1/7 (14) | N | N | N | Y | N | N | N |
| Death | 3/42 (7) | 2/7 (29) | N | N | Y | N | N | Y | N |
| Ongoing disease |
32/42 (76) |
4/7 (71) |
Y |
Y |
N |
N |
Y |
N |
Y |
| Underlying conditions | |||||||||
| Corticotherapy‡ | 1/42 (2) | 2/7 (29) | Y | Y | N | N | N | N | N |
| Other immunosuppression‡ | 5/42 (12) | 0/7 (0) | N | N | N | N | N | N | N |
| Smoking‡ | 15/42 (36) | 2/7 (29) | N | Y | Y | N | N | N | N |
| Cardiovascular diseases | 1/42 (2) | 6/7 (90) | Y | Y | Y | Y | Y | Y | N |
| Chronic respiratory disease | 4/42 (10) | 1/7 (14) | N | Y | N | N | N | N | N |
| Chronic renal insufficiency | 1/42 (2) | 1/7 (14) | N | N | N | N | N | Y | N |
| Diabetes‡ | 10/42 (24) | 2/7 (29) | N | Y | N | N | Y | N | N |
| Hemopathy or cancer‡ | 3/42 (7) | 2/7 (29) | Y | N | Y | N | N | N | N |
| ≥1 underlying condition |
25/42 (60) |
6/7 (86) |
Y |
Y |
Y |
Y |
Y |
Y |
N |
| Exposures§ | |||||||||
| Hospital‡ | 1/42 (2) | 2/7 (0) | Y | Y | N | N | N | N | N |
| Nursing home‡ | 2/42 (5) | 0/7 (0) | N | N | N | N | N | N | N |
| Travel associated/tourismঠ| 11/42 (26) | 1/7 (29) | N | Y | N | N | N | N | N |
| Professional exposure‡# | 2/42 (5) | 0/7 (0) | N | N | N | N | N | N | N |
| Other exposure‡** | 0/42 (0) | 1/7 (29) | N | N | N | N | Y | N | N |
| ≥1 exposure | 14/42 (33) | 3/7 (43) | Y | Y | N | N | Y | N | N |
*Values are no. patients/total no. in category (%) except as indicated. COVID-19, coronavirus disease; ICU, intensive care unit; LD, Legionnaires’ disease. †Demographics and outcome at the LD notification date. ‡Elements indicated in mandatory LD notifications. LD risk exposures had to be reported if they occurred ≤14 d before LD symptom onset. §Exposures were indicated in LD mandatory notifications. ¶Travel-associated/tourism exposures include hotels, holiday resorts, rental houses, and cruises. #Professional exposures include using public showers during work hours. **Other exposure: in-house plumbing.
1Members are listed at the end of this article.